ArticleJournal of medicinal chemistry2026

Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers.

Lingying Leng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.